Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2191]

Phase III results of olaparib for BRCA breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

Self-reporting symptoms online improves patient care, chemotherapy duration and...

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of...

Self-reporting symptoms online improves patient care, chemotherapy duration and survival ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy

Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )

Expert prostate discussion: Clinical diagnostics, genomics, systemic and...

Dr Chris Parker and Prof Charles Ryan

Expert prostate discussion: Clinical diagnostics, genomics, systemic and radiological treatment ( Dr Chris Parker and Prof Charles Ryan )

3 or 6 months adjuvant oxaliplatin for colorectal cancer

Dr Tim Iveson - University Hospital Southampton, Salisbury, UK

3 or 6 months adjuvant oxaliplatin for colorectal cancer ( Dr Tim Iveson - University Hospital Southampton, Salisbury, UK )

Pooled analysis of avelumab for metastatic urothelial carcinoma

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pooled analysis of avelumab for metastatic urothelial carcinoma ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers ( Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA )

Routine genomic testing is feasible, but only a subset of patients benefit

Dr Olivier Trédan - Centre Léon Bérard, Lyon, France

Routine genomic testing is feasible, but only a subset of patients benefit ( Dr Olivier Trédan - Centre Léon Bérard, Lyon, France )

Molecular profiles and the future of adjuvant therapy

Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiles and the future of adjuvant therapy ( Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Pregnancy after breast cancer no associated with relapse risk

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

Pregnancy after breast cancer no associated with relapse risk ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )

Delaying metastatic prostate cancer, improving survival with abiraterone

Prof Karim Fizazi - Institut Gustave Roussy, Paris, France

Delaying metastatic prostate cancer, improving survival with abiraterone ( Prof Karim Fizazi - Institut Gustave Roussy, Paris, France )

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression...

Prof Nick James - Queen Elizabeth Hospital Birmingham & University of...

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/deaths ( Prof Nick James - Queen Elizabeth Hospital Birmingham & University of Birmingham, UK )

More from ecancer